Nuvation Bio gets FDA approval for IBTROZI® label update
FDA approved Nuvation Bio’s supplemental new drug application for IBTROZI® (taletrectinib), updating TRUST-I data to reflect a nearly 50-month median duration of response in TKI-naïve advanced ROS1-positive non-small cell lung cancer.